# Psilocybin, MDMA, and LSD

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/psilocybin-mdma-and-lsd
Canonical HTML page: https://getbiobrief.com/entity/psilocybin-mdma-and-lsd

## Timeline

- **2026-09-08**: HHS fills four senior FDA roles — The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
- **2026-05**: Hoeg departs CDER — Dr. Tracy Beth Hoeg said she was fired from the Center for Drug Evaluation and Research; Davis began serving in an acting role.
- **2025**: Davis returns to FDA — Michael Davis rejoined the agency as a deputy director after working at a nonprofit pursuing psychedelic drug development.

## Recent coverage (1 stories)

### FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
2026-09-09 21:53:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.
Full story: https://getbiobrief.com/story/fda-psychedelic-drug-chief-vaccine-director-biotech-impact-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.